Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2012

View Archived Issues

Researchers at Allergan prepare new S1P1 receptor ligands

TiGenix reports on phase I Cx-621 trial

Tissue Therapies provides update on CE mark application for wound-healing product

PAION receives government grant for thrombomodulin mutants

DiscoveryBioMed receives funding to support metabolic diseases drug discovery program

Safety results presented on new MedImmune immunotherapeutic

AMG-900 shows promise in first-in-human trial

Scientists discover cause of Sengers syndrome / News in Context

Navitoclax administered with bendamustine/rituximab in phase I study

Dinaciclib is highly active in phase I trial in chronic lymphocytic leukemia

ImmunoCellular Therapeutics to expand enrollment in ICT-107 trial

FDA grants priority review for ocriplasmin BLA

Alla Chem discloses novel antivirals

New agents for leukemia developed in U.S.

Novel chemokine receptor antagonists patented by Emory University

New beta-amyloid inhibitors designed in Japan

Constellation Pharmaceuticals presents new inhibitors of bromodomain-containing proteins

Biogen Idec and Isis to collaborate on myotonic dystrophy program

Ferring Pharmaceuticals gains licensing rights to IBAT inhibitor

Takeda reports novel anticancer agents

Drug discovery collaboration begins for postpartum hemorrhage

BioDelivery Sciences reports on BEMA-buprenorphine/naloxone study

Leukemia & Lymphoma Society and Celator expand partnership

CBio discloses planned merger

FDA accepts NDA for once-weekly contraceptive patch

EC decides in favor of SkyePharma product's approval for asthma

Spectrum Pharmaceuticals launches phase II lucanthone trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...